Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PUR003

Other · developed by Pulmatrix

Phase 1 Most advanced trial (none active)
PULM Developer
1 Registered trials

What is PUR003?

PUR003 is an agent delivered by twice-daily inhalation via a commercially available nebulizer for 7 days. It was studied in healthy volunteers in relation to influenza.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Infectious disease
Developer
Pulmatrix Inc. (PULM)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT00947687 Phase 1 Healthy Completed PULM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Healthy

More from Pulmatrix

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the PULM page.

Follow PULM, the company behind PUR003

See PULM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PULM catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.